Search Results
Your search for 3 matches 15291 pages
Showing 351 - 400CRISPR-Cas9-Edited TILs: Targeting Intracellular Immune Checkpoint CISH in Metastatic Colorectal Cancer
In a first-in-human, single-institution phase I trial reported in The Lancet Oncology, Lou et al found that autologous tumor-infiltrating lymphocytes (TILs) genetically edited with CRISPR-Cas9 to target the intracellular immune checkpoint CISH were tolerable and showed evidence of activity in...
In Case You Missed It: Additional Abstracts of Interest From AACR
Thousands of forward-looking research studies defined the 2025 American Association for Cancer Research (AACR) Annual Meeting. Here, aside from our fuller coverage of key presentations in The ASCO Post, we offer a snapshot of a few additional abstracts that may be of interest to cancer researchers...
FDA Approves Doublet for KRAS-Mutated, Recurrent, Low-Grade Serous Ovarian Cancer
Today, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the combination of the dual RAF/MEK inhibitor avutometinib and the FAK inhibitor defactinib (Avmapki Fakzynja Co-pack) for adults with KRAS-mutated, recurrent, low-grade serous ovarian cancer (LGSOC) who have...
Breast Cancer Radiotherapy: 1- vs 3-Week Course
A 1-week course of postsurgery radiotherapy demonstrated comparable safety and efficacy to the traditional 3-week regimen in patients with early-stage breast cancer, according to new findings presented by Brunt et al at the European Society for Radiotherapy and Oncology (ESTRO) 2025 Annual Meeting...
Ablative Radiation Therapy for Resectable Pancreatic Ductal Adenocarcinoma
Ablative radiation therapy is considered to be an alternative to surgery, providing an effective noninvasive option for local treatment of many types of cancer, but it is unknown whether ablative radiation therapy is effective for pancreatic ductal adenocarcinoma. Surgery provides improved...
ASH Studies Bolster Support for Menin Inhibitor in Acute Leukemia
The recent approval of the oral menin inhibitor revumenib brought much-needed treatment to patients with a challenging subset of disease: adults and children with relapsed or refractory acute leukemia harboring a lysine methyltransferase 2A gene (KMT2A) translocation or rearrangement. Approval was...
Final Overall Survival Data: Amivantamab-vmjw Plus Lazertinib vs Osimertinib in EGFR-Mutated Non–Small Cell Lung Cancer
The phase III MARIPOSA trial was a head-to-head comparison of the EGFR tyrosine kinase inhibitor osimertinib and the combination of the bispecific EGF receptor–directed and MET receptor–directed monoclonal antibody amivantamab-vmjw and the EGFR tyrosine kinase inhibitor lazertinib in the first-line ...
Off-the-Shelf Natural Killer CAR T-Cell Therapy Shows Efficacy in Small Study of Relapsed or Refractory Blood Cancers
The U.S. Food and Drug Administration (FDA) approved the first chimeric antigen receptor (CAR) T-cell therapy in 2017 to treat children with acute lymphoblastic leukemia.1 Over the past decade, other CAR T-cell therapies have been FDA approved to treat adults with blood cancers, including...
Study Shows Disparities in Diagnosing Endometrial Cancer in Women With Postmenopausal Bleeding
Angela Nolin, MD, a gynecologic oncology fellow at Duke University Health System in Durham, North Carolina, and colleagues conducted a multi-institutional study to determine whether racial differences in transvaginal ultrasound efficacy combined with timely receipt of indicated endometrial...
Quick Takes on Research Findings on Novel Therapies for Gynecologic Cancers
The 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer advanced the field with updates of practice-changing trials and other research that challenges the conventional approaches to treating gynecologic cancers. We have briefly captured some of that research here for readers ...
Survival Trends in Melanoma Brain Metastases: Update of Melanoma Graded Prognostic Assessment
In a study reported in Journal of Clinical Oncology, Sperduto and colleagues analyzed trends in survival associated with newly diagnosed melanoma brain metastases and updated the Melanoma Graded Prognostic Assessment (GPA). Study Details The study involved retrospective data from...
Everolimus Plus Lanreotide vs Everolimus Alone in Aggressive Gastroenteropancreatic Neuroendocrine Tumors
In patients with aggressive gastroenteropancreatic neuroendocrine tumors, first-line treatment with the mTOR inhibitor everolimus and the somatostatin analog lanreotide more than doubled the median progression-free survival for patients vs everolimus alone, in the phase III JCOG1901 (STARTER-NET)...
Radiotherapy for Prostate Cancer: 2- vs 8-Week Course
The phase III HYPO-RT-PC trial has shown that a 2-week course of radiotherapy for localized prostate cancer—also known as ultra-hypofractionated radiotherapy—may be just as safe and effective as the traditional 8-week schedule—even 10 years after treatment. The findings were presented at the 2025...
AML: MRD Testing Led to Survival Benefits in Subset of Patients
Sequential molecular measurable residual disease (MRD) testing and monitoring led to a survival benefit among younger patients with acute myeloid leukemia (AML) and NPM1 and FLT3-ITD mutations, according to the results of a study published in The Lancet Haematology. Patients with both mutations...
Addition of Perioperative Pembrolizumab to Standard of Care in Newly Diagnosed Locally Advanced Head and Neck Cancer
In the phase III KEYNOTE-689 trial, perioperative use of the PD-1 inhibitor pembrolizumab given with standard therapy significantly improved event-free survival in newly diagnosed, previously untreated patients with locally advanced head and neck squamous cell carcinoma, researchers reported at the ...
Dose Escalation of Fluorodeoxyglucose PET–Guided Radiotherapy for Locally Advanced NSCLC
In an analysis from the Scandinavian phase III NARLAL2 trial, reported in the Journal of Clinical Oncology, Schytte et al found that fluorodeoxyglucose (FDG)-PET–guided heterogeneously dose-escalated radiotherapy was not associated with greater 6-month toxicity vs standard radiotherapy in...
Adavosertib in Recurrent or Persistent Uterine Serous Carcinoma
In the phase IIb ADAGIO trial, reported in the Journal of Clinical Oncology, Liu et al found that the Wee1 inhibitor adavosertib showed some activity in patients with recurrent or persistent uterine serous carcinoma. However, its use was associated with high toxicity rates. Study Details In the...
Use of Ruxolitinib to Resolve Ciltacabtagene Autoleucel–Induced Parkinsonism in Patients With Multiple Myeloma
Ruxolitinib may prove to be an effective treatment of parkinsonism arising from ciltacabtagene autoleucel treatment for patients with multiple myeloma, according to the results of a case report published in the Journal of Hematology. The report featured two cases of patients with multiple myeloma...
AACR 2025: Novel CAR T-Cell Therapy Induces Response in Patients With Advanced Thyroid Cancers
A novel chimeric antigen receptor (CAR) T-cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety profile in patients with two types of advanced thyroid cancer. Results from a small, first-in-human phase I trial were presented at the ...
AACR 2025: Topical BRAF Inhibitor Under Study for Managing Acneiform Rash
Compared with a placebo gel, an investigational topical BRAF inhibitor (LUT014) was found to improve the symptoms of acneiform rash in patients with colorectal cancer. These phase II clinical trial results were presented by Anisha B. Patel, MD, Associate Professor of Dermatology, Deputy Chair of...
AACR 2025: Sex Disparities Identified in Fatigue and Depression for Cancer Survivors
Female cancer survivors are more likely to experience cancer-related fatigue and depression than male cancer survivors, and those with cancer-related fatigue and/or depression are almost two times as likely to reduce their recreational activities, according to the results of a retrospective study...
AACR 2025: Oral HER2-Targeted Therapy for Advanced HER2-Mutated Lung Cancer
The novel HER2-targeted tyrosine kinase inhibitor zongertinib elicited durable responses in patients with advanced, previously treated non–small cell lung cancer (NSCLC) that harbored a HER2 mutation, according to the preliminary results of the early-phase Beamion LUNG-1 trial. These findings were...
AACR 2025: Off-the-Shelf Natural Killer CAR Therapy Active in Hematologic Malignancies
The U.S. Food and Drug Administration (FDA) approved the first chimeric antigen receptor (CAR) T-cell therapy in 2017 to treat children with acute lymphoblastic leukemia. Over the past decade, other CAR T-cell therapies have been FDA-approved to treat adults with blood cancers, including...
AACR 2025: Use of ctDNA-Based Liquid Biopsy Assay in Resectable Colorectal Cancer
Interim results from the VICTORI study showed that an ultrasensitive circulating tumor DNA (ctDNA)-based liquid biopsy assay was effective in detecting signs of cancer recurrence prior to imaging and provided prognostic value within 1 month after surgery in patients with colorectal cancer. The...
Addition of Neoadjuvant/Adjuvant Pembrolizumab Significantly Improves Outcomes in Locally Advanced HNSCC
The addition of neoadjuvant and adjuvant pembrolizumab to standard-of-care therapy significantly improved event-free survival over the standard of care alone for patients with locally advanced head and neck cancer in the phase III KEYNOTE-689 trial, according to results presented at the American...
Omission of Endocrine Therapy in Estrogen Receptor–Low, Early-Stage Breast Cancer
In a study reported in the Journal of Clinical Oncology, Choong et al found that omission of endocrine therapy in patients with estrogen receptor–low (1%–10% on immunohistochemistry), early-stage breast cancer was not associated with improved survival outcomes. The study used National Cancer...
Use of Statins in CLL/SLL
Statin use during targeted therapy treatment led to a 61% improvement in the risk of dying of cancer for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to the results of a study published in Blood Advances. The investigators sought to determine the...
Case 3: Third-Line Treatment of CLL With Deletion 13q, Trisomy 12, and Unmutated IGHV
This is Part 3 of Treatment Approaches to Relapsed/Refractory CLL: What Comes Next, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Nicole Lamanna, John Allan, and Inhye Ahn discuss the third-line treatment of chronic...
FDA Approves Anti–PD-1 Antibody for Nasopharyngeal Cancer
The U.S. Food and Drug Administration (FDA) has approved the humanized IgG1 monoclonal anti–PD-1 antibody penpulimab-kcqx with cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic nonkeratinizing nasopharyngeal carcinoma (NPC). The FDA also...
Case 3: Patient With Recurrent Chromophobe RCC
This is Part 3 of New Approaches to Treatment Sequencing in Advanced Renal Cell Carcinoma, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Daniel George, Michael Harrison, and Catherine Fahey discuss the treatment of recurrent ...
Combination Immunotherapy Approved for Unresectable or Metastatic Hepatocellular Carcinoma
On April 11, 2025, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo) with ipilimumab (Yervoy) for the first-line treatment of adults with unresectable or metastatic hepatocellular carcinoma. (See here for details on approval of this combination immunotherapy for colorectal...
Use of Investigational Tool to Detect Advanced-Stage Invasive Cervical Cancer
At the 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, Kersten Rothnie, MBBS, a gynecologic oncology fellow at Northwell Health in New York City, shared study findings on an investigational tool on behalf of her colleagues.1 These results suggested the presence of...
Managing Dermatologic Reactions to Combination Therapy for Patients With EGFR-Mutated NSCLC
Nicolas Girard, MD, a thoracic oncologist at the Institut Curie, Paris, presented the results of an interim analysis of the open-label phase II COCOON study, at the European Lung Cancer Congress (ELCC) 2025.1 A readily available preventive regimen (the COCOON regimen) reduced moderate-to-severe...
Several Trials Show Clinical Activity With Osimertinib in Advanced EGFR-Mutant Non–Small Cell Lung Cancer
Updates from several clinical trials of the EGFR tyrosine kinase inhibitor osimertinib across stages and settings of EGFR-mutated non–small cell lung cancer (NSCLC) were presented at the European Lung Cancer Congress (ELCC) 2025. The updated results from the phase III LAURA trial were presented by ...
Is This the End of Cancer Research as We Know It?
Ongoing efforts to rein in government spending have been described as a “chainsaw for bureaucracy.” It’s an apt metaphor for the haphazard budget cuts that many federal agencies are still experiencing. On February 7, 2025, the chainsaw made its way to facilities and administrative (F&A)...
Benefits of Walnut Consumption: Curbing Inflammation, Colorectal Cancer Risk
Researchers have uncovered that eating walnuts may improve systemic inflammation and reduce the risk for colorectal cancer, according to a recent study published by Moussa et al in Cancer Prevention Research. Background Ellagitannins—plant-derived polyphenol compounds found in walnuts—have been...
Addition of Daratumumab to Treatment Regimen in Transplant-Ineligible, Newly Diagnosed Multiple Myeloma
As reported in The Lancet Oncology by Mateos et al, the final results of the phase III ALCYONE trial showed persistent benefit with the addition of daratumumab to bortezomib, melphalan, and prednisone (D-VMP) in transplant-ineligible patients with newly diagnosed multiple myeloma. The primary...
Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma
In a Dutch trial (UPGRADE-RT) reported in the Journal of Clinical Oncology, van den Bosch et al found that definitive radiotherapy with reduced-dose elective neck irradiation was safe and effective compared with standard-dose elective neck irradiation in patients with head and neck squamous cell...
Extended Follow-up of Belzutifan Treatment for von Hippel–Lindau Disease–Associated Renal Cell Carcinoma
In extended follow-up of the phase II LITESPARK-004 trial reported in The Lancet Oncology, Srinivasan et al found that use of the hypoxia-inducible factor-2α inhibitor belzutifan was associated with maintained benefit in patients with von Hippel–Lindau disease–associated renal cell carcinoma. The...
Therapy With a Tyrosine Kinase Inhibitor for EGFR-Variant Lung Adenocarcinoma: Lessons From Chronic Myeloid Leukemia?
There has been remarkable progress in treating EGFR-variant lung adenocarcinoma with tyrosine kinase inhibitors such as gefitinib, erlotinib, osimertinib, and afatinib. However, several important issues remain unresolved, including whether there remains a role for chemotherapy, who should receive a ...
Adaptive Manufactured Lentiviral Anti-CD20/Anti-CD19 CAR T Cells in Relapsed/Refractory Mantle Cell Lymphoma
In a single-center phase I/II study reported in the Journal of Clinical Oncology, Shah et al found that adaptive manufactured lentiviral anti-CD20/anti-CD19 (LV20.19) chimeric antigen receptor (CAR) T-cell treatment was highly active in relapsed or refractory mantle cell lymphoma. Study Details In...
Some Patients With Advanced NSCLC Experience Durable Disease Control After Immunotherapy Discontinuation
Although immune checkpoint inhibitors (ICIs) have transformed the treatment landscape over the last decade for patients with non–small cell lung cancer (NSCLC), the agents can also stimulate uncontrolled immunity against normal tissues and organs, leading to a cascade of immune-related adverse...
Advanced Esophageal Cancer: NOTCH1 Mutation and Efficacy of Tislelizumab
In an analysis from the phase III RATIONALE-302 trial reported in the Journal of Clinical Oncology, Lu et al found that the presence of NOTCH1 mutation was associated with improved overall survival in patients receiving second-line tislelizumab vs investigator’s choice of chemotherapy for advanced...
Dual Use of Cigarettes and E-Cigarettes on Par With Sole Cigarette Use in Terms of Toxic Exposure
Individuals who reported exclusive use of combustible cigarettes as well as those who reported dual use of both cigarettes and e-cigarettes showed similarly high toxicant exposure, according to the results of a study published in Nicotine & Tobacco Research. Both groups of smokers showed higher ...
Case 3: Perioperative Strategies for a Patient With Muscle-Invasive Bladder Cancer and Borderline Renal Function
This is Part 3 of Immunotherapy Approaches in Muscle-Invasive Bladder Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Matthew Galsky, Srikala Sridhar, and Abhishek Tripathi discuss perioperative treatment strategies...
Can ctDNA Monitoring Help to Predict Melanoma Recurrence?
A new study showed that approximately 80% of patients with stage III melanoma who had detectable levels of circulating tumor DNA (ctDNA) before they started treatment to suppress their tumors went on to experience recurrence. Researchers also found that the disease returned more than four times...
Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer
In the French phase II PANACHE01-PRODIGE48 trial, researchers found that neoadjuvant chemotherapy with mFOLFIRINOX (modified leucovorin, fluorouracil, irinotecan, and oxaliplatin) was feasible and active in patients with resectable pancreatic adenocarcinoma. Schwarz et al published these findings...
Most Pediatric Cancer Deaths Occur in Regions of Conflict
Almost 60% of all deaths from pediatric cancers occur in regions of armed conflict, according to the results of a study published in The Lancet Oncology. Investigators from St. Jude Children’s Research Hospital, Duke University, and other institutions sought to reveal the relationship between...
Metastatic Castration-Resistant Prostate Cancer: Immune-Modulating ADC Targeting CD46
In a phase I study reported in the Journal of Clinical Oncology, Aggarwal et al reported activity with the antibody-drug conjugate (ADC) FOR46 in patients with metastatic castration-resistant prostate cancer. As stated by the investigators, “FOR46, a fully human antibody conjugated to monomethyl...
FDA Approves Nivolumab Plus Ipilimumab for Unresectable or Metastatic HCC
On April 11, 2025, the U.S. Food and Drug Administration approved nivolumab (Opdivo) with ipilimumab (Yervoy) for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC). Efficacy was evaluated in CheckMate-9DW (ClinicalTrials.gov identifier...
